Key Points
- Director sold 2,627 shares: Corazon (Corsee) Sanders sold 2,627 BeOne Medicines shares on Nov. 26 at an average price of $340.90 for a total of $895,544, per an SEC Form 4 filing.
- BeOne trades around $335–$341 with a market cap of about $39.8 billion, a very high P/E (~658), and a 1‑year range of $170.99 to $385.22, reflecting elevated valuation despite recent strength.
- Analyst and institutional view: the stock has an average rating of Moderate Buy with a $365.79 average target, and large investors like Primecap and Temasek recently established sizable new stakes (institutional ownership ~48.6%).
BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) Director Corazon (Corsee) Sanders sold 2,627 shares of BeOne Medicines stock in a transaction on Wednesday, November 26th. The shares were sold at an average price of $340.90, for a total value of $895,544.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
BeOne Medicines Price Performance
Shares of NASDAQ ONC opened at $335.60 on Tuesday. The stock's 50-day moving average is $332.67 and its two-hundred day moving average is $300.46. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.39 and a quick ratio of 2.17. The company has a market cap of $39.78 billion, a price-to-earnings ratio of 658.04 and a beta of 0.45. BeOne Medicines Ltd. - Sponsored ADR has a 1-year low of $170.99 and a 1-year high of $385.22.
Analyst Upgrades and Downgrades
Several brokerages recently weighed in on ONC. Truist Financial set a $400.00 target price on shares of BeOne Medicines in a report on Monday, November 24th. Zacks Research downgraded shares of BeOne Medicines from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, October 28th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of BeOne Medicines in a research report on Wednesday, October 8th. Jefferies Financial Group reiterated a "buy" rating and set a $420.00 target price on shares of BeOne Medicines in a research note on Monday, November 17th. Finally, Guggenheim raised their price target on BeOne Medicines from $350.00 to $365.00 and gave the company a "buy" rating in a research note on Thursday, August 7th. Twelve analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, BeOne Medicines currently has an average rating of "Moderate Buy" and an average target price of $365.79.
Get Our Latest Analysis on ONC
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of the stock. Primecap Management Co. CA purchased a new stake in BeOne Medicines in the second quarter valued at $1,231,720,000. Temasek Holdings Private Ltd acquired a new stake in shares of BeOne Medicines during the second quarter worth about $244,603,000. Marshall Wace LLP purchased a new stake in shares of BeOne Medicines in the 2nd quarter valued at about $113,190,000. Baird Financial Group Inc. acquired a new stake in shares of BeOne Medicines in the 2nd quarter valued at about $82,895,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in BeOne Medicines during the 2nd quarter worth approximately $73,347,000. 48.55% of the stock is owned by hedge funds and other institutional investors.
BeOne Medicines Company Profile
(
Get Free Report)
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
